Evaluation of Regenerative Potential in Horizontal Bone Loss Using VCMX Along With LASER Therapy

Launched by POSTGRADUATE INSTITUTE OF DENTAL SCIENCES ROHTAK · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with horizontal bone loss caused by periodontitis, which is a serious gum disease that can lead to tooth loss. The researchers want to see if a combination of a special collagen material called VCMX and low-level laser therapy (LLLT) can help regenerate bone in the jaw. This is important because restoring bone can help support teeth and improve oral health. The study will involve 60 participants, who will be divided into three groups: one receiving the VCMX with laser treatment, another receiving only laser treatment, and a control group receiving standard treatment.

To participate in this trial, individuals must have stage 2 or 3 periodontitis and horizontal bone loss that is at least 5 mm deep. Other criteria include having healthy teeth that are not decayed or restored, and not being on certain medications that could impact the study's results. Participants can expect to undergo evaluations at the start of the study and again at 3, 6, and 9 months to assess their periodontal health and bone regeneration. This trial is a unique opportunity to explore a potential new way to improve bone healing in patients with gum disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Periodontitis stage 2 and stage 3 patients will be enrolled according to criteria of 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions
• • Horizontal bone loss defects with depth ≥ 5 mm (initially analyzed by trans-gingival probing and intraoral periapical radiographs and will be confirmed further after flap elevation and CBCT)
• • PPD ≥ 5 mm
• • CAL ≥ 3 mm
• • Tooth mobility \< grade 1
• • Experimental teeth and adjacent teeth would be required to be vital and free of caries or dental restorations
• Exclusion Criteria:
• • Any systemic illness that could affect the periodontium or outcome of periodontal therapy
• • patients on medications such as corticosteroids or calcium channel blockers
• • long-term nonsteroidal anti-inflammatory drug therapy
• • pregnant or lactating women
• • current and past smoker
• • Periodontitis stage 4
• • teeth with one-wall defect, the presence of exostoses and ledges, grade II and grade III mobile teeth, defects extending to a root furcation area, unrestorable teeth, fractured/perforated roots, developing permanent teeth, endodontically treated teeth, and teeth with premature contact and dental prosthesis.